Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/gastroesophageal Junction Cancer Based on the Multi-omics Information During Tumor Evolution.

NCT06642857 is registered in ClinicalTrials.gov with Xiangdong Cheng as lead sponsor.

NCT NCT06642857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06642857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/gastroesophageal Junction Cancer Based on the Multi-omics Information During Tumor Evolution.
Lead sponsor
Xiangdong Cheng
Phase
Observational
Overall status
Recruiting
Start date
March 25, 2024
Completion date
February 1, 2026
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric carcinoma, advanced gastroesophageal junction adenocarcinoma